gemfibrozil and Hyperlipemia studies

Research Excerpts

Excerpt	Relevance	Reference
"This was a post hoc subgroup analysis in the Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1."	9.11	Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. ( Bloomfield, H; Collins, D; Curhan, GC; Robins, S; Tonelli, M, 2004)
"To examine the effects of gemfibrozil on very-low-density lipoprotein (VLDL) composition and low-density lipoprotein (LDL) size, five men with hypertriglyceridemia (HTG) alone and five men with HTG and hypercholesterolemia (combined hyperlipidemia, CHLP) were randomized for 8 weeks to Lopid SR (slow-release gemfibrozil; two 600-mg tablets once per day) or placebo in a crossover study."	9.08	Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. ( Gotto, AM; Gu, ZW; Quion, JA; Valentinova, NV; Xie, YH; Yang, CY; Yang, M; Yeshurun, D, 1996)
"To compare the lipid-lowering efficacies of simvastatin and gemfibrozil in NIDDM patients with combined (mixed) hyperlipidemia (CHL) or isolated hypercholesterolemia (IHC)."	9.08	Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. ( Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ, 1998)
"To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias."	9.07	[Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias]. ( Batlouni, M; Bertolami, MC; Bismarck, ZF; Faludi, AA; Martinez, TL; Melo, RS; Pinto, LE, 1991)
"Gemfibrozil is a fibrate drug."	7.77	[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. ( Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C, 1992)
"To report a case of rhabdomyolysis and acute renal failure associated with gemfibrozil monotherapy of hyperlipidemia."	7.72	Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. ( Layne, RD; Sehbai, AS; Stark, LJ, 2004)
"We report a patient with renal insufficiency who developed rhabdomyolysis 1 month after initiating cerivastatin and gemfibrozil for hyperlipidemia."	7.71	Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. ( Kind, AH; McBride, PE; Zakowski, LJ, 2002)
"To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease."	7.71	Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ( Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002)
"Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis."	7.70	A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. ( Boran, M; Gökçe, V; Koçak, B; Korkmaz, S; Ozdemir, O; Uzun, Y, 2000)
" We describe a case of severe myopathy and rhabdomyolysis associated with concomitant use of simvastatin and gemfibrozil."	7.69	Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. ( Isley, W; Rajeshawari, M; Tal, A, 1997)
"To present a case of gemfibrozil-induced myositis which precipitated an acute compartment syndrome."	7.68	Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. ( Chow, LT; Chow, WH, 1993)
"Mixed hyperlipidemia is a common risk factor for cardiovascular disease."	6.70	Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001)
"Smoking and dyslipidemia are more potent risk factors for nonfatal MI in males who have the -344C allele of CYP11B2."	6.69	Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. ( Hautanen, A; Kayes, KM; Kupari, M; Manninen, V; Mänttäri, M; Rosenfeld, S; Tenkanen, L; Toivanen, P; White, PC, 1999)
" These differences may be due to interactions between genetic and environmental factors that effect drug bioavailability or the capacity of the lipid-regulating enzyme and receptor targets to be affected."	5.30	Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. ( Ballesta, AM; Casals, E; Ojuel, J; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Zambón, D, 1998)
"This was a post hoc subgroup analysis in the Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1."	5.11	Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. ( Bloomfield, H; Collins, D; Curhan, GC; Robins, S; Tonelli, M, 2004)
"To compare the lipid-lowering efficacies of simvastatin and gemfibrozil in NIDDM patients with combined (mixed) hyperlipidemia (CHL) or isolated hypercholesterolemia (IHC)."	5.08	Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. ( Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ, 1998)
"To examine the effects of gemfibrozil on very-low-density lipoprotein (VLDL) composition and low-density lipoprotein (LDL) size, five men with hypertriglyceridemia (HTG) alone and five men with HTG and hypercholesterolemia (combined hyperlipidemia, CHLP) were randomized for 8 weeks to Lopid SR (slow-release gemfibrozil; two 600-mg tablets once per day) or placebo in a crossover study."	5.08	Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. ( Gotto, AM; Gu, ZW; Quion, JA; Valentinova, NV; Xie, YH; Yang, CY; Yang, M; Yeshurun, D, 1996)
" In this study, the area under the curve, maximum plasma concentration, and time to maximum concentration for fluvastatin and gemfibrozil are compared, when used alone and in combination, in patients with hyperlipidemia and either coronary or carotid atherosclerosis, or a family history of coronary artery disease."	5.08	Pharmacokinetics of the combination of fluvastatin and gemfibrozil. ( Hendricks, L; Khouri, HE; Latchinian, L; Munoz, CE; Spence, JD, 1995)
"To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias."	5.07	[Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias]. ( Batlouni, M; Bertolami, MC; Bismarck, ZF; Faludi, AA; Martinez, TL; Melo, RS; Pinto, LE, 1991)
"A multicentric, double-blind and randomized clinical study was conducted on a total of 54 patients with hyperlipidemias type IIa, IIb and IV in order to compare the effectivity and tolerance of two hyperlipemiant drugs: Binifibrate and Gemfibrozil."	5.07	[Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia]. ( Anguera Vila, A; Ariño Armengol, B; Corominas Vilardell, A; de Oya Otero, M; Escobar Jiménez, F, 1993)
"During screening in the Helsinki Heart Study (HHS), a 5-year coronary primary prevention trial with gemfibrozil, some 600 dyslipidaemic individuals were detected who exhibited symptoms and signs of possible coronary heart disease (CHD)."	5.07	Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M, 1993)
" The study has the following 3 key objectives: to define the cost effectiveness of gemfibrozil in the prevention of coronary heart disease (CHD); to assess the net impact of gemfibrozil on total treatment costs for CHD; and to identify those patient groups for whom gemfibrozil therapy is most cost effective."	5.06	Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy. ( Fifer, SK; Sarma, S, 1990)
"A 34% reduction in the incidence of definite coronary heart disease events was observed in dyslipidemic men treated with gemfibrozil in the Helsinki Heart Study, a controlled 5-year, double-blind primary prevention trial for coronary heart disease."	5.06	Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Manninen, V; Tenkanen, L, 1989)
"Gemfibrozil is a fibrate drug."	3.77	[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. ( Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C, 1992)
"An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis."	3.72	Risk of adverse events with fibrates. ( Alsheikh-Ali, AA; Karas, RH; Kuvin, JT, 2004)
"To report a case of rhabdomyolysis and acute renal failure associated with gemfibrozil monotherapy of hyperlipidemia."	3.72	Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. ( Layne, RD; Sehbai, AS; Stark, LJ, 2004)
" Eight subjects had hypertriglyceridemia (HTG) and low high-density lipoprotein (HDL), 14 had combined hyperlipidemia (CH), 5 had the apo E2/2 genotype receiving gemfibrozil, 10 were normolipidemic (NL) controls, and 4 had hypercholesterolemia."	3.71	Postprandial remnant-like lipoproteins in hypertriglyceridemia. ( Cousins, M; Nakajima, K; Ooi, DS; Ooi, TC; Simo, IE; Steiner, G; Uffelman, KD, 2001)
"To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease."	3.71	Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ( Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002)
"We report a patient with renal insufficiency who developed rhabdomyolysis 1 month after initiating cerivastatin and gemfibrozil for hyperlipidemia."	3.71	Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. ( Kind, AH; McBride, PE; Zakowski, LJ, 2002)
"Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis."	3.70	A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. ( Boran, M; Gökçe, V; Koçak, B; Korkmaz, S; Ozdemir, O; Uzun, Y, 2000)
"The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil."	3.70	Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. ( Keng, HC; Rindone, JP, 1998)
" We describe a case of severe myopathy and rhabdomyolysis associated with concomitant use of simvastatin and gemfibrozil."	3.69	Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. ( Isley, W; Rajeshawari, M; Tal, A, 1997)
"To present a case of gemfibrozil-induced myositis which precipitated an acute compartment syndrome."	3.68	Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. ( Chow, LT; Chow, WH, 1993)
" In 55 patients (20 on HD, 13 on CAPD and 22 NDCRF) with severe hypertriglyceridemia or diminished HDL cholesterol gemfibrozil 300 mg b."	3.68	Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. ( Dardamanis, MA; Elisaf, MS; Papagalanis, ND; Siamopoulos, KC, 1993)
" The absence of a significant pharmacokinetic interaction between fenofibrate and atorvastatin is consistent with recent results showing no difference in safety profile between atorvastatin as monotherapy or in combination with fenofibric acid."	2.76	Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. ( Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR, 2011)
"The present study showed 212 hyperlipidemia with osteopenia patients of which 106 patients in statin group had mean age (63."	2.75	Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. ( Chuengsamarn, S; Kaufman, L; Rattanamongkoulgul, S; Suwanwalaikorn, S; Wattanasirichaigoon, S, 2010)
"Posttransplant hyperlipidemia increases cardiovascular morbidity and mortality rate in renal transplant recipients."	2.74	Effects of diet and gemfibrozil on posttransplant hyperlipidemia in renal transplant recipients. ( Ozben, B; Ozben, T; Sapan, M; Suleymanlar, G; Yakupoglu, G, 2009)
"Ezetimibe is a novel lipid-lowering drug that prevents intestinal absorption of dietary and biliary cholesterol leading to significant reduction in total-C, LDL-C, Apo B, and TG and increases in HDL-C in patients with hypercholesterolemia."	2.71	Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. ( Affrime, M; Batra, V; Boutros, T; Kosoglou, T; Maxwell, SE; Pember, L; Reyderman, L; Statkevich, P, 2004)
"In the control group (n=18), a hypolipidemiant diet alone was indicated."	2.71	Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. ( Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R, 2003)
"For this purpose, 22 patients with type 2 diabetes and combined dyslipidemia were randomized to treatment with either a statin or gemfibrozil for 3 months."	2.70	Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia. ( Abbasi, F; Lamendola, C; Leary, E; McLaughlin, T; Reaven, GM, 2002)
"Mixed hyperlipidemia is a common risk factor for cardiovascular disease."	2.70	Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001)
"Pravastatin and gemfibrozil therapy is safe and efficacious in patients with mixed hyperlipidemia."	2.69	Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. ( Iliadis, EA; Rosenson, RS, 1999)
"Gemfibrozil treatment alone reduced the CK increments 8 hours postexercise by 47% and the FABP increments 1 and 8 hours postexercise by 83% and 101%, respectively (all P < ."	2.69	Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention. ( De Bruin, TW; Eekhoff, EM; Erkelens, DW; Glatz, J; Smit, JW, 1999)
"91 patients with hyperlipidemia were randomly divided into a treatment group (n = 47, Xuezhikang 1."	2.69	[The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia]. ( Deng, C; Hao, X; Jian, J; Lin, J; Zhou, H, 1999)
"Smoking and dyslipidemia are more potent risk factors for nonfatal MI in males who have the -344C allele of CYP11B2."	2.69	Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. ( Hautanen, A; Kayes, KM; Kupari, M; Manninen, V; Mänttäri, M; Rosenfeld, S; Tenkanen, L; Toivanen, P; White, PC, 1999)
"Gemfibrozil treatment lowered plasma triglycerides and both total and very low-density lipoprotein (VLDL)-cholesterol (P < 0."	2.69	Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. ( Aberg, F; Angelin, B; Appelkvist, EL; Bröijersén, A; Dallner, G; Eriksson, M; Hjemdahl, P, 1998)
" Each patient was followed up at Out-patient Clinic regularly for diet interview, compliance and possible adverse events."	2.68	Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study. ( Chen, JW; Jen, SL; Lee, WL; Wang, SP, 1997)
"Gemfibrozil or placebo was given in a double-blind cross-over fashion to 14 patients, who after 8 weeks of acitretin therapy and dietary advice exhibited hyperlipidemia (triglyceride levels > or = 50% above baseline and/or > or = 2."	2.68	Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. ( Lindholm, A; Olsson, AG; Vahlquist, A; Vahlquist, C, 1995)
"Lovastatin reduced pretreatment levels of atherogenic and triglyceride-rich lipoprotein components and slowed post-treatment increases compared with no drug therapy."	2.68	Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments. ( Alaupovic, P; Dudley, VS; Knight-Gibson, C; Lane, DM; Laughlin, LO, 1995)
"Patients with NIDDM have a two- to fourfold increased risk of macrovascular disease."	2.67	Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators. ( Colwell, JA; Vinik, AI, 1993)
"We compared the efficacy of three formulations and two dosage regimens of gemfibrozil in 322 dyslipidemic (non-high-density lipoprotein [HDL] cholesterol level, greater than or equal to 5."	2.67	Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers. ( Koskinen, P; Kovanen, PT; Manninen, V; Tuomilehto, J, 1992)
"Fifty nine cases with hyperlipidemia were divided randomly into two groups."	2.67	[Clinical evaluation of simvastatin in the treatment of hyperlipidemia]. ( Lu, ZL, 1993)
"Gemfibrozil was given randomly either alone, with, 2 hours before, or 2 hours after 5 grams of colestipol."	2.67	Apparent reduced absorption of gemfibrozil when given with colestipol. ( Cutler, RE; Feng, Y; Forland, SC, 1990)
"Gemfibrozil was the least effective of all drugs but decreased the lipid and protein contents and their ratios in VLDL and LDL-2."	2.67	Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. ( Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G, 1990)
"Exaggerated postprandial hyperlipidemia has been associated with cardiovascular disease."	2.41	Postprandial lipemia--effect of lipid-lowering drugs. ( Karpe, F, 2002)
" Recently, a new tablet formulation of micronised fenofibrate has become available with greater bioavailability than the older capsule formulation."	2.41	Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. ( Keating, GM; Ormrod, D, 2002)
"Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance."	2.39	Drug interactions with fibric acids. ( Dujovne, CA; Lozada, A, 1994)
"Gemfibrozil has shown efficacy in the treatment of patients with type IIa, IIb, III, IV or V dyslipidaemia or hypoalphalipoproteinaemia, especially in patients with elevated triglyceride and low HDL cholesterol levels."	2.39	Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. ( Barradell, LB; Spencer, CM, 1996)
"Hyperlipidemia is a well-recognized complication of renal transplantation."	2.38	Hyperlipidemia and transplantation: etiologic factors and therapy. ( Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Knechtle, SJ; Pirsch, JD; Reed, A; Sollinger, HW, 1992)
"Gemfibrozil is a lipid-regulating agent which is generically classified as a fibric acid derivative, but which exhibits different pharmacological effects from other such drugs."	2.37	Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. ( Todd, PA; Ward, A, 1988)
"Hyperlipidemia should be managed systematically using information about the association between increased lipid concentrations and CAD, patient risk factors, and limitations of both diet and drug therapy."	2.37	Contemporary recommendations for evaluating and treating hyperlipidemia. ( Perry, RS, 1986)
"Because the complications of hyperlipidemia are caused mainly by TC, thereby, by maintaining it at a normal level, we could set a TG target by the linear equation that allowed a certain degree of hypertriglyceridemia."	1.56	Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I. ( Hong, YH; Ma, MS; Qiu, ZQ; Sun, ZX; Wei, M; Xu, YW; Yuan, YH; Zhang, ZJ, 2020)
"Andrographolide (1) has been identified as one of the active constituents against atherosclerosis."	1.39	Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity. ( Bhatia, G; Pandeti, S; Shukla, A; Sonkar, R; Tadigoppula, N, 2013)
"Over the last three decades, hypolipemiants like fibric acid derivatives and statins have been increasingly recognised as causes of rhabdomyolysis and acute renal failure especially during combination therapy and in the presence of underlying renal impairment."	1.31	Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. ( Kamaliah, MD; Sanjay, LD, 2001)
"Gemfibrozil has been shown to have beneficial effects in the primary and secondary prevention of atherosclerosis."	1.31	Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia. ( Alfón, J; Badimon, L; Berrozpe, M; Royo, T, 2000)
"A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction."	1.30	Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997)
" These differences may be due to interactions between genetic and environmental factors that effect drug bioavailability or the capacity of the lipid-regulating enzyme and receptor targets to be affected."	1.30	Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. ( Ballesta, AM; Casals, E; Ojuel, J; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Zambón, D, 1998)
"A 61-year-old woman with hyperlipidemia was treated with gemfibrozil."	1.29	[Gemfibrozil-induced myopathy]. ( Adler, Y; Aron, A; Weiss, P, 1993)
"Patients with chronic renal failure appear at greater risk for skeletal muscle side effects from the fibric acid group of lipid lowering agents."	1.29	Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. ( Irish, A; Kemp, GJ; Radda, GK; Taylor, DJ; Thompson, CH, 1996)
"Gemfibrozil treatment in non-PiZ patients also resulted in a reduction of alpha 1-AT activity which could be reproduced in vitro."	1.29	An interaction between Gemfibrozil and alpha 1-antitrypsin. ( Eriksson, S; Janciauskiene, S, 1994)
"The hyperlipidemia had not been treated before, and a cholesterol-reduced diet did not succeed in lowering total cholesterol below 6."	1.28	Effect of gemfibrozil on erythrocyte membrane lipids in geriatric patients. ( Bauer, M; Hager, K; Platt, D, 1990)
"Gemfibrozil was well tolerated in the dose of 1200 mg/day and no dropouts were attributable to its use."	1.28	Gemfibrozil in hyperlipidaemia: an open, single blind trial. ( Joshi, VR; Nihalani, KD; Salgaonkar, DS; Sharma, SS; Turakhia, DP; Varthakavi, PK, 1990)
"Gemfibrozil caused an increase in HDL cholesterol."	1.28	[Gemfibrozil in the treatment of hyperlipidemia]. ( Lin, WH; Song, YM; Wang, JJ; Wang, YS, 1989)
" Most of these drugs have side effects which, in the elderly, may necessitate lower dosing than usual."	1.27	Treating hyperlipidemia, Part III: Drug therapy. ( Brown, WV; Karmally, W; Smith, DA, 1987)
"Experimental hyperlipidemia was induced in ddY, C57BL, BALB and ICR strain mice and in Wistar rats."	1.27	[Strains and species differences in experimental hyperlipidemia]. ( Hirai, Y; Kawakami, M; Koyama, S; Mishima, Y; Mizutani, A; Morishita, S; Saito, T, 1986)
"Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia."	1.27	Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986)
" Adverse side effects ranging from mere annoyances to uncommon serious consequences may be associated with dietary modification, recreational physical exercise, and drug intervention."	1.27	Adverse effects of the treatment for hyperlipidemia. ( Malinow, MR, 1986)

Research

Studies (219)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

All-Cause Death

Timeframe	Studies, this research(%)	All Research%
pre-1990	31 (14.16)	18.7374
1990's	103 (47.03)	18.2507
2000's	74 (33.79)	29.6817
2010's	10 (4.57)	24.3611
2020's	1 (0.46)	2.80

Authors	Studies
Sethi, A	1
Maurya, A	1
Tewari, V	1
Srivastava, S	1
Faridi, S	1
Bhatia, G	6
Khan, MM	1
Khanna, AK	4
Saxena, JK	2
Sashidhara, KV	4
Rosaiah, JN	2
Idrees, GA	1
Aly, OM	1
Abuo-Rahma, Gel-D	1
Radwan, MF	1
Kumar, A	1
Kumar, M	1
Sonkar, R	3
Singh, BS	1
Palnati, GR	1
Dodda, RP	1
Pandeti, S	1
Shukla, A	1
Tadigoppula, N	1
Zhang, ZJ	1
Yuan, YH	1
Ma, MS	1
Hong, YH	1
Sun, ZX	1
Xu, YW	1
Wei, M	1
Qiu, ZQ	1
Arya, N	1
Munde, MK	1
Dwivedi, J	1
Jagdale, AY	1
Jain, KS	2
Rai, H	1
Dhaneshwar, SS	1
Bertolotti, M	1
Del Puppo, M	1
Gabbi, C	1
Corna, F	1
Carulli, L	1
Pellegrini, E	1
Zambianchi, L	1
Anzivino, C	1
Ricchi, M	1
Loria, P	1
Kienle, MG	1
Carulli, N	1
McBride, P	1
Sapan, M	1
Ozben, B	1
Yakupoglu, G	1
Suleymanlar, G	1
Ozben, T	1
Roy, A	1
Pahan, K	1
Abourbih, S	1
Filion, KB	1
Joseph, L	1
Schiffrin, EL	1
Rinfret, S	1
Poirier, P	1
Pilote, L	1
Genest, J	1
Eisenberg, MJ	2
Chuengsamarn, S	1
Rattanamongkoulgul, S	1
Suwanwalaikorn, S	1
Wattanasirichaigoon, S	1
Kaufman, L	1
Whitfield, LR	1
Porcari, AR	1
Alvey, C	1
Abel, R	1
Bullen, W	1
Hartman, D	1
Qandil, AM	1
Rezigue, MM	1
Tashtoush, BM	1
Bossé, Y	1
Vohl, MC	1
Dumont, M	3
Brochu, M	1
Bergeron, J	3
Després, JP	3
Prud'homme, D	3
Naik, NS	1
Ganotakis, E	1
Tsimihodimos, V	1
Bairaktari, E	2
Rizos, E	1
Athyros, V	1
Seferiades, C	1
Elisaf, M	2
Keating, GM	1
Ormrod, D	1
Kolovou, GD	1
Cokkinos, DV	1
McLaughlin, T	1
Abbasi, F	1
Lamendola, C	1
Leary, E	1
Reaven, GM	1
Kind, AH	1
Zakowski, LJ	1
McBride, PE	1
Colagiuri, S	1
Best, J	1
Corbelli, JC	1
Bullano, MF	1
Willey, VJ	1
Cziraky, MJ	1
Corbelli, ME	1
Waugh, W	1
Packard, KA	1
Backes, JM	1
Lenz, TL	1
Wurdeman, RL	1
Destache, C	1
Hilleman, DE	1
Farnier, M	3
Bortolini, M	1
Salko, T	2
Freudenreich, MO	1
Isaacsohn, JL	2
Troendle, AJ	2
Gonasun, L	2
Hernández, C	1
Lecube, A	1
Barberá, G	1
Chacón, P	1
Lima, J	1
Simó, R	1
Lemieux, I	1
Pascot, A	1
Alméras, N	1
Nadeau, A	1
Garber, AJ	1
Boden, WE	1
Kervinen, H	1
Huittinen, T	1
Vaarala, O	1
Leinonen, M	1
Saikku, P	1
Manninen, V	9
Mänttäri, M	5
Rizvi, F	1
Iftikhar, M	1
George, JP	1
Dejager, S	1
Ballantyne, CM	1
Davidson, MH	1
Shammas, NW	1
Kapalis, MJ	1
Deckert, J	1
Harris, M	1
Dippel, EJ	1
Labroo, A	1
McKinney, D	1
Layne, RD	1
Sehbai, AS	1
Stark, LJ	1
Jamal, SM	1
Christopoulos, S	1
Ascaso, JF	1
Fernández-Cruz, A	1
González Santos, P	1
Hernández Mijares, A	1
Mangas Rojas, A	1
Millán, J	1
Felipe Pallardo, L	1
Pedro-Botet, J	1
Pérez-Jiménez, F	1
Pía, G	1
Pintó, X	1
Plaza, I	1
Rubiés-Prat, J	1
Alsheikh-Ali, AA	1
Kuvin, JT	1
Karas, RH	1
Reyderman, L	1
Kosoglou, T	1
Statkevich, P	1
Pember, L	1
Boutros, T	1
Maxwell, SE	1
Affrime, M	1
Batra, V	1
Tonelli, M	1
Collins, D	1
Robins, S	1
Bloomfield, H	1
Curhan, GC	1
Wägner, AM	1
Ordóñez-Llanos, J	1
Jorba, O	1
Pérez, A	1
Duez, H	1
Lefebvre, B	1
Poulain, P	1
Torra, IP	2
Percevault, F	1
Luc, G	1
Peters, JM	1
Gonzalez, FJ	1
Gineste, R	1
Helleboid, S	1
Dzavik, V	1
Fruchart, JC	3
Fiévet, C	1
Lefebvre, P	1
Staels, B	2
Sigal, R	2
Malcolm, J	2
Meggison, H	1
Maghzal, GJ	1
Brennan, SO	1
George, PM	1
Milionis, HJ	1
Elisaf, MS	3
Mikhailidis, DP	1
Sutken, E	1
Inal, M	1
Ozdemir, F	1
Bloomfield, HE	1
Trivedi, NR	1
Cong, Z	1
Nelson, AM	1
Albert, AJ	1
Rosamilia, LL	1
Sivarajah, S	1
Gilliland, KL	1
Liu, W	1
Mauger, DT	1
Gabbay, RA	1
Thiboutot, DM	1
Titov, VN	1
Arapbaeva, AA	1
Kukharchuk, VV	1
Balakina, MV	1
Tishinin, MA	1
Ameliushkina, VA	1
Arnaout, A	1
Movahed, MR	1
Samsamsharaiat, SA	1
Kathiravan, MK	1
Shishoo, CJ	1
Kumar, KG	1
Roy, SK	1
Mahadik, KR	1
Kadam, SS	1
Landry, P	1
Dimitri, E	1
Tessier, S	1
Légaré, N	1
Kesäniemi, YA	1
Grundy, SM	3
Nash, DT	2
Fenderson, RW	1
Deutsch, S	1
Menachemi, E	1
Chin, B	1
Samuel, P	1
Lewis, JE	1
Mälkönen, M	1
Muona, M	1
Tiula, E	1
Alikoski, T	1
Smit, JW	2
Jansen, GH	1
de Bruin, TW	2
Erkelens, DW	3
Spence, JD	1
Munoz, CE	1
Hendricks, L	1
Latchinian, L	1
Khouri, HE	1
Vanhanen, HT	1
Miettinen, TA	1
Lane, DM	1
Alaupovic, P	1
Knight-Gibson, C	1
Dudley, VS	1
Laughlin, LO	1
Lozada, A	1
Dujovne, CA	2
Kumar, H	1
Morales, E	1
Spinler, SA	1
Wilson, MD	1
Chin, MM	1
Jozefiak, E	1
Chan, TM	1
Cheng, IK	1
Tam, SC	1
Wolf, HR	1
Kuo, PT	1
Rosenson, RS	2
Frauenheim, WA	1
Janciauskiene, S	1
Eriksson, S	1
Corominas Vilardell, A	1
de Oya Otero, M	1
Escobar Jiménez, F	1
Anguera Vila, A	1
Ariño Armengol, B	1
de Alava, E	1
Sola, JJ	1
Lozano, MD	1
Pardo-Mindán, FJ	1
Lu, ZL	1
Vartanova, OA	1
Aleksandrovskaia, TN	1
Shaldaeva, VV	1
Knoll, RW	1
Ciafone, R	1
Galen, M	1
Aron, A	1
Adler, Y	1
Weiss, P	1
Olsson, AG	2
Van Buren, CT	2
Javela, K	1
Koskinen, P	3
Pikkarainen, J	1
Huttunen, JK	3
Frick, MH	3
McNabb, TR	1
Chow, LT	1
Chow, WH	1
Vinik, AI	1
Colwell, JA	1
Heinonen, OP	3
Stelmach, WJ	1
Rush, DR	1
Brucker, PC	1
Schaefer, EJ	1
Holverson, HE	1
Kane, WJ	1
Huffman, BL	1
Gotto, AM	4
Breen, WJ	1
Corder, CN	1
Dunn, JK	1
Goldberg, A	1
Knopp, RH	1
Schrott, H	1
Sprecher, D	1
Dardamanis, MA	1
Papagalanis, ND	1
Siamopoulos, KC	1
Reichl, D	1
Miller, NE	1
Sterchi, JM	1
Peters, JR	1
Kubo, SH	1
Olivari, MT	1
Knutson, KR	1
Hunninghake, DB	2
Jogestrand, T	2
Fehrman-Ekholm, I	2
Angelin, B	4
Berglund, L	1
Gäbel, H	1
Abdul-Ghaffar, NU	1
el-Sonbaty, MR	1
Vahlquist, C	1
Lindholm, A	1
Vahlquist, A	1
Nemeth, A	1
Szakmary, K	1
Kramer, J	1
Dinya, E	1
Pados, G	1
Fust, G	1
Huettinger, M	1
Lundgren, C	1
Sobel, BE	1
Fujii, S	1
Spencer, CM	1
Barradell, LB	1
Fasching, P	2
Rohac, M	2
Liener, K	1
Schneider, B	1
Nowotny, P	1
Waldhäusl, W	2
Tikkanen, MJ	3
Thompson, CH	2
Irish, A	1
Kemp, GJ	1
Taylor, DJ	1
Radda, GK	1
Knipscheer, HC	2
de Valois, JC	1
van den Ende, B	1
Wouter ten Cate, J	1
Kastelein, JJ	2
Bröijersén, A	2
Hamsten, A	1
Silveira, A	1
Fatah, K	1
Goodall, AH	1
Eriksson, M	2
Hjemdahl, P	2
Spencer, GA	1
Wirebaugh, S	1
Whitney, EJ	2
Yang, CY	1
Gu, ZW	1
Xie, YH	1
Valentinova, NV	1
Yang, M	1
Yeshurun, D	1
Quion, JA	1
Górriz, JL	1
Sancho, A	1
Lopez-Martin, JM	1
Alcoy, E	1
Catalán, C	1
Pallardó, LM	1
Lang, JE	1
Wang, P	1
Glueck, CJ	1
Stone, NJ	1
Irish, AB	1
Schiel, R	1
Bambauer, R	1
Müller, UA	1
de Maat, MP	1
Kluft, C	1
Perreault, S	1
Hamilton, VH	1
Lavoie, F	1
Grover, S	1
Farmer, JA	1
Tal, A	1
Rajeshawari, M	1
Isley, W	1
Jen, SL	1
Chen, JW	1
Lee, WL	1
Wang, SP	1
Stapleton, DD	1
Mehra, MR	1
Dumas, D	1
Smart, FW	1
Milani, RV	1
Lavie, CJ	1
Ventura, HO	1
Kesten, S	1
Mayne, L	1
Scavuzzo, M	1
Maurer, J	1
Andrews, TC	1
Green, G	1
Kalenian, R	1
Personius, BE	1
Migdalis, IN	1
Gerolimou, B	1
Kozanidou, G	1
Voudouris, G	1
Hatzigakis, SM	1
Petropoulos, A	1
Lucatello, A	1
Sturani, A	1
Di Nardo, AM	1
Cocchi, R	1
Fusaroli, M	1
Aberg, F	1
Appelkvist, EL	1
Dallner, G	1
Laakso, M	1
Ilmonen, M	1
Helve, E	1
Kaarsalo, E	1
Kilkki, E	1
Saltevo, J	1
Sanllehy, C	1
Casals, E	1
Rodriguez-Villar, C	1
Zambón, D	1
Ojuel, J	1
Ballesta, AM	1
Ros, E	1
Hoogerbrugge, N	1
Kerkhofs, LG	1
Jansen, H	1
Koenig, W	1
Habib, A	1
Merval, R	1
Lebret, M	1
Delerive, P	1
Fadel, A	1
Chinetti, G	1
Najib, J	1
Maclouf, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396]	Phase 2	701 participants (Actual)	Interventional	2020-08-18	Completed
A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined With Prednisone-Free, Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation[NCT00166712]	Phase 4	40 participants (Actual)	Interventional	2005-04-30	Terminated (stopped due to Study stopped due to lack of efficacy & funding.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days

Exploratory Hierarchical Composite Endpoint

Intervention	Participants (Count of Participants)
Fenofibrate + Usual Care	19
Placebo + Usual Care	22

The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days

Number of Days Alive and Out of the Hospital During the 30 Days Following Randomization

Intervention	score on a scale (Median)
Fenofibrate + Usual Care	5.03
Placebo + Usual Care	5.03

Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days

Number of Days Alive, Out of the Intensive Care Unit, Free of Mechanical Ventilation/Extracorporeal Membrane Oxygenation, or Maximal Available Respiratory Support in the 30 Days Following Randomization

Intervention	days (Median)
Fenofibrate + Usual Care	30
Placebo + Usual Care	30

Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days

Primary Hierarchical Composite Endpoint

Intervention	days (Mean)
Fenofibrate + Usual Care	28.8
Placebo + Usual Care	28.3

The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days

Secondary Hierarchical Composite Endpoint

Intervention	Ranked Severity Score (Median)
Fenofibrate + Usual Care	5.32
Placebo + Usual Care	5.33

The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days

Seven-category Ordinal Scale

Intervention	score on a scale (Median)
Fenofibrate + Usual Care	5.05
Placebo + Usual Care	5.05

A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days

The Incidence of Biopsy-proven Acute Allograft Rejection During the First 12 Months of Transplant.

Intervention	score on a scale (Median)
Fenofibrate + Usual Care	1
Placebo + Usual Care	1

The incidence of rejection is determined by the proportion of patients experiencing biopsy proven acute allograft rejection during the first 12 months post-transplant. (NCT00166712)
Timeframe: Within 12 months post kidney transplant

Intervention	Participants (Number)
Groups	4
Group 2	6

Article	Year
Triglycerides and risk for coronary artery disease. Current atherosclerosis reports, 2008, Volume: 10, Issue:5 Topics: Alcohol Drinking; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Hydroxym	2008
Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacology and immunotoxicology, 2009, Volume: 31, Issue:3 Topics: Cell Communication; Cell Movement; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Infla	2009
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. The American journal of medicine, 2009, Volume: 122, Issue:10 Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Fe	2009
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 2002, Volume: 62, Issue:13 Topics: Cardiovascular Diseases; Databases, Bibliographic; Diabetes Mellitus, Type 2; Drug Delivery Systems;	2002
Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment. Current medical research and opinion, 2002, Volume: 18, Issue:5 Topics: Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Risk	2002
Lipid-lowering therapy in people with type 2 diabetes. Current opinion in lipidology, 2002, Volume: 13, Issue:6 Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reducta	2002
Cardiovascular complications of diabetes: prevention and management. Clinical cornerstone, 2003, Volume: 5, Issue:2 Topics: Blood Pressure; Diabetic Angiopathies; Disease Progression; Gemfibrozil; Humans; Hydroxymethylglutar	2003
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Current opinion in cardiology, 2003, Volume: 18, Issue:4 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Thera	2003
Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature. Preventive cardiology, 2003,Fall, Volume: 6, Issue:4 Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Red	2003
Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2003, Volume: 3, Issue:3 Topics: Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglu	2003
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. American heart journal, 2004, Volume: 147, Issue:6 Topics: Cyclosporine; Cytochrome P-450 CYP4A; Dose-Response Relationship, Drug; Drug Interactions; Gemfibroz	2004
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:5 Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Human	2004
Prevention of cardiovascular events in diabetes. Clinical evidence, 2004, Issue:11 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Corona	2004
Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Current medical research and opinion, 2000, Volume: 16, Issue:1 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylg	2000
Prevention of cardiovascular events in diabetes. Clinical evidence, 2006, Issue:15 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid	2006
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation, 1984, Volume: 69, Issue:5 Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl	1984
Drug interactions with fibric acids. Pharmacology & therapeutics, 1994, Volume: 63, Issue:2 Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Dru	1994
Dyslipidemia and coronary artery disease. Clinical cardiology, 1994, Volume: 17, Issue:10 Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H	1994
Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs, 1996, Volume: 51, Issue:6 Topics: Clinical Trials as Topic; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents	1996
Selection of appropriate type and intensity of lipid-lowering therapy. Current opinion in lipidology, 1995, Volume: 6, Issue:6 Topics: Cholesterol; Clinical Trials as Topic; Coronary Disease; Diet; Endothelium, Vascular; Enzyme Inhibit	1995
Lipid management: current diet and drug treatment options. The American journal of medicine, 1996, Oct-08, Volume: 101, Issue:4A Topics: Diet; Gemfibrozil; Humans; Hyperlipidemias; Niacin; Patient Education as Topic	1996
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6 Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf	1997
Choosing the right lipid-regulating agent. A guide to selection. Drugs, 1996, Volume: 52, Issue:5 Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat	1996
Pharmacology department: pharmacologic approaches to abnormal blood lipids. The Journal of cardiovascular nursing, 2000, Volume: 14, Issue:2 Topics: Anion Exchange Resins; Antioxidants; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Red	2000
Normocholesterolaemic dyslipidaemia: is there a role for fibrates? The Medical journal of Australia, 2001, Jan-15, Volume: 174, Issue:2 Topics: Bezafibrate; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypol	2001
[Helsinki Heart Study]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Adult; Coronary Disease; Finland; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids	2001
[Gemfibrozil: new aspects in clinical use]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hyperli	2001
Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol. The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Combinations; Ethanol; Gemfibrozil; Humans; Hydroxy	2000
Postprandial lipemia--effect of lipid-lowering drugs. Atherosclerosis. Supplements, 2002, Volume: 3, Issue:1 Topics: Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym	2002
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. Cardiologia (Rome, Italy), 1992, Volume: 37, Issue:11 Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia;	1992
Hyperlipidemia and transplantation: etiologic factors and therapy. Journal of the American Society of Nephrology : JASN, 1992, Volume: 2, Issue:12 Suppl Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Coronary Disease; Diuretics; Gemfibrozil; Humans;	1992
Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs, 1988, Volume: 36, Issue:3 Topics: Gemfibrozil; Humans; Hyperlipidemias	1988
When to treat hyperlipidemia. Advances in internal medicine, 1988, Volume: 33 Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H	1988
Reducing cardiac deaths with hypolipidemic drugs. Postgraduate medicine, 1987, Nov-01, Volume: 82, Issue:6 Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfi	1987
Contemporary recommendations for evaluating and treating hyperlipidemia. Clinical pharmacy, 1986, Volume: 5, Issue:2 Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lip	1986
The diagnosis and management of hyperlipidemia. Disease-a-month : DM, 1986, Volume: 32, Issue:5 Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr	1986

Article	Year
Effects of diet and gemfibrozil on posttransplant hyperlipidemia in renal transplant recipients. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2009, Volume: 57, Issue:2 Topics: Adult; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantat	2009
Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone, 2010, Volume: 46, Issue:4 Topics: Aged; Bone Density; Bone Diseases, Metabolic; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA	2010
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. Journal of clinical pharmacology, 2011, Volume: 51, Issue:3 Topics: Adult; Atorvastatin; Biotransformation; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Fe	2011
Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clinical genetics, 2002, Volume: 62, Issue:1 Topics: Administration, Oral; Adult; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metab	2002
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia. Metabolism: clinical and experimental, 2002, Volume: 51, Issue:10 Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hydroxym	2002
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Medical science monitor : international medical journal of experimental and clinical research, 2003, Volume: 9, Issue:3 Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hy	2003
Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology, 2003, Apr-01, Volume: 23, Issue:4 Topics: Adult; Body Constitution; C-Reactive Protein; Coronary Artery Disease; Gemfibrozil; Humans; Hyperlip	2003
Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. International journal of clinical pharmacology and therapeutics, 2004, Volume: 42, Issue:9 Topics: Administration, Oral; Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Azetidines; Cro	2004
Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, Volume: 44, Issue:5 Topics: Aged; Cholesterol, HDL; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; F	2004
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes. Metabolism: clinical and experimental, 2004, Volume: 53, Issue:11 Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL;	2004
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:3 Topics: Adolescent; Adult; Aged; Animals; Apolipoprotein A-I; Cholesterol, HDL; Female; Fenofibrate; Gemfibr	2005
Effects of vitamin E and gemfibrozil on lipid profiles, lipid peroxidation and antioxidant status in the elderly and young hyperlipidemic subjects. Saudi medical journal, 2006, Volume: 27, Issue:4 Topics: Adult; Age Factors; Aged; Antioxidants; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic	2006
Peroxisome proliferator-activated receptors increase human sebum production. The Journal of investigative dermatology, 2006, Volume: 126, Issue:9 Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlip	2006
Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA, 1984, May-04, Volume: 251, Issue:17 Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Clofibrate;	1984
Effect of gemfibrozil on serum lipids in man. Angiology, 1982, Volume: 33, Issue:9 Topics: Adult; Aged; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clin	1982
Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia. Angiology, 1982, Volume: 33, Issue:9 Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans	1982
Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension (Dallas, Tex. : 1979), 1995, Volume: 26, Issue:4 Topics: Adult; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Creatin	1995
Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. The American journal of cardiology, 1995, Jul-13, Volume: 76, Issue:2 Topics: Anticholesteremic Agents; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase;	1995
Pharmacokinetics of the combination of fluvastatin and gemfibrozil. The American journal of cardiology, 1995, Jul-13, Volume: 76, Issue:2 Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Stenosis; Coronary Artery Disease; Coronary Dise	1995
Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis, 1995, Volume: 115, Issue:2 Topics: Absorption; Apolipoproteins; Cholestanol; Cholesterol; Double-Blind Method; Drug Therapy, Combinatio	1995
Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments. The American journal of cardiology, 1995, Jun-01, Volume: 75, Issue:16 Topics: Adult; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Blood Component Removal; Chemical Prec	1995
Hyperlipidemia after renal transplantation: treatment with gemfibrozil. Nephron, 1994, Volume: 67, Issue:3 Topics: Adult; Cholesterol; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney Transplan	1994
Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia. Drugs under experimental and clinical research, 1994, Volume: 20, Issue:3 Topics: Cholesterol; Cholesterol, HDL; Clofibric Acid; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolip	1994
[Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia]. Anales de medicina interna (Madrid, Spain : 1984), 1993, Volume: 10, Issue:11 Topics: Adolescent; Adult; Aged; Apoproteins; Cholesterol; Double-Blind Method; Female; Gemfibrozil; Humans;	1993
[Clinical evaluation of simvastatin in the treatment of hyperlipidemia]. Zhonghua xin xue guan bing za zhi, 1993, Volume: 21, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholester	1993
Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators. Diabetes care, 1993, Volume: 16, Issue:1 Topics: C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gemfibrozil; Glycated Hemoglobin;	1993
Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Annals of medicine, 1993, Volume: 25, Issue:1 Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Gemfi	1993
Diet and exercise and gemfibrozil therapy for the management of dyslipidemia: a CEN study. Clinical Experience Network. The Journal of family practice, 1993, Volume: 36, Issue:4 Topics: Cholesterol; Combined Modality Therapy; Dietary Fats; Exercise; Family Practice; Female; Gemfibrozil	1993
Once-daily, extended-release gemfibrozil in patients with dyslipidemia. The Lopid SR Work Group I. The American journal of cardiology, 1993, May-01, Volume: 71, Issue:12 Topics: Adolescent; Adult; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Administration Sched	1993
Gemfibrozil increases apolipoprotein A-I and cholesterol concentrations in human peripheral lymph. European journal of clinical investigation, 1993, Volume: 23, Issue:4 Topics: Adult; Aged; Apolipoprotein A-I; Biological Transport, Active; Cholesterol; Gemfibrozil; Humans; Hyp	1993
Increased prevalence of atherosclerotic wall changes in patients with hyperlipidaemia after renal transplantation. Journal of internal medicine, 1996, Volume: 239, Issue:2 Topics: Adult; Arteriosclerosis; Carotid Artery, Common; Double-Blind Method; Female; Gemfibrozil; Humans; H	1996
Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Acta dermato-venereologica, 1995, Volume: 75, Issue:5 Topics: Acitretin; Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Dose-Re	1995
Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:5 Topics: Aged; Blood Glucose; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fish Oils;	1996
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia. Atherosclerosis, 1996, Volume: 124 Suppl Topics: Adult; Aged; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Follow-Up Studie	1996
Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation. Nephron, 1996, Volume: 72, Issue:3 Topics: Cyclosporine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents;	1996
Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thrombosis and haemostasis, 1996, Volume: 76, Issue:2 Topics: Adult; Aged; Analysis of Variance; Cross-Over Studies; Double-Blind Method; Factor VII; Factor VIIa;	1996
Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. Atherosclerosis, 1996, Sep-27, Volume: 126, Issue:1 Topics: Adult; Apolipoproteins E; Cross-Over Studies; Enzyme-Linked Immunosorbent Assay; Gemfibrozil; Humans	1996
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. The International journal of artificial organs, 1995, Volume: 18, Issue:12 Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol,	1995
Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Thrombosis and haemostasis, 1997, Volume: 77, Issue:1 Topics: Adult; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypol	1997
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6 Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf	1997
Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1997, Volume: 59, Issue:4 Topics: Adult; Aged; Cross-Over Studies; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipi	1997
Lipid-lowering therapy and long-term survival in heart transplantation. The American journal of cardiology, 1997, Sep-15, Volume: 80, Issue:6 Topics: Adult; Cholesterol; Cohort Studies; Female; Gemfibrozil; Heart Transplantation; Humans; Hyperlipidem	1997
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. The American journal of cardiology, 1997, Oct-01, Volume: 80, Issue:7 Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Co	1997
Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia. International angiology : a journal of the International Union of Angiology, 1997, Volume: 16, Issue:4 Topics: Administration, Oral; Arteriosclerosis; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Comm	1997
Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. European journal of clinical investigation, 1998, Volume: 28, Issue:3 Topics: Adult; Aged; Antioxidants; Apolipoproteins; Case-Control Studies; Coronary Disease; Cross-Over Studi	1998
Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes care, 1998, Volume: 21, Issue:4 Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes M	1998
Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia. Journal of internal medicine, 1998, Volume: 243, Issue:5 Topics: Adult; Aged; Autoantibodies; Disease Progression; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemi	1998
Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis, 1998, Volume: 139, Issue:1 Topics: Adult; Aged; Apolipoproteins; Arteriosclerosis; Double-Blind Method; Fatty Acids, Nonesterified; Fem	1998
Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabetic medicine : a journal of the British Diabetic Association, 1998, Volume: 15, Issue:10 Topics: Blood Coagulation; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Gemfib	1998
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clinical cardiology, 1999, Volume: 22, Issue:1 Topics: Cholesterol, HDL; Cholesterol, LDL; Creatine; Creatine Kinase; Drug Therapy, Combination; Female; Fo	1999
Intensive lipid-lowering strategy in patients with diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 1999, Volume: 16, Issue:6 Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes	1999
Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation, 1999, Nov-30, Volume: 100, Issue:22 Topics: Adult; Aldosterone; Alleles; Baroreflex; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; C	1999
Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention. Metabolism: clinical and experimental, 1999, Volume: 48, Issue:12 Topics: Double-Blind Method; Drug Therapy, Combination; Exercise; Exercise Test; Fatty Acids, Monounsaturate	1999
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. Metabolism: clinical and experimental, 2001, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Apolipoproteins B; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol,	2001
Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25, Issue:8 Topics: Adipose Tissue; Area Under Curve; Blood Glucose; Cholesterol; Gemfibrozil; Glucose Tolerance Test; H	2001
[The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia]. Zhonghua nei ke za zhi, 1999, Volume: 38, Issue:8 Topics: Aged; Drugs, Chinese Herbal; Epoprostenol; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidem	1999
Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides. Maturitas, 2002, May-20, Volume: 42, Issue:1 Topics: Administration, Oral; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estr	2002
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. Cardiologia (Rome, Italy), 1992, Volume: 37, Issue:11 Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia;	1992
Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Annals of internal medicine, 1992, Dec-01, Volume: 117, Issue:11 Topics: Adult; Attitude of Health Personnel; Clinical Trials as Topic; Data Interpretation, Statistical; Gem	1992
Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis, 1992, Volume: 95, Issue:1 Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperl	1992
Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers. Archives of internal medicine, 1992, Volume: 152, Issue:1 Topics: Apolipoproteins B; Chemistry, Pharmaceutical; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug	1992
Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification. Transplantation, 1992, Volume: 53, Issue:1 Topics: Dietary Carbohydrates; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemias; Kidney Transplantation; P	1992
[Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias]. Arquivos brasileiros de cardiologia, 1991, Volume: 56, Issue:5 Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholestero	1991
Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients. Kidney international. Supplement, 1991, Volume: 31 Topics: Cholestyramine Resin; Colestipol; Food, Formulated; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Lo	1991
[Fish oil as lipostatic factor]. VASA. Supplementum, 1990, Volume: 30 Topics: Adult; Diabetic Angiopathies; Female; Fish Oils; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Male;	1990
Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions. Current medical research and opinion, 1990, Volume: 12, Issue:4 Topics: Adult; Aged; Arterial Occlusive Diseases; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipide	1990
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis, 1990, Volume: 85, Issue:2-3 Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Choleste	1990
Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy. Drugs, 1990, Volume: 40 Suppl 1 Topics: Adult; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle A	1990
Gemfibrozil in dyslipidaemia. The Journal of the Association of Physicians of India, 1990, Volume: 38, Issue:2 Topics: Adult; Cholesterol; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female;	1990
Effect of gemfibrozil administration on biliary lipid secretion in hyperlipidemic patients. A crossover study with clofibrate. Scandinavian journal of gastroenterology, 1990, Volume: 25, Issue:12 Topics: Adult; Aged; Bile; Bile Acids and Salts; Cholesterol; Clofibrate; Female; Gemfibrozil; Humans; Hyper	1990
Apparent reduced absorption of gemfibrozil when given with colestipol. Journal of clinical pharmacology, 1990, Volume: 30, Issue:1 Topics: Aged; Biological Availability; Cholesterol; Colestipol; Drug Interactions; Gemfibrozil; Humans; Hype	1990
Management of primary mixed hyperlipidemia with lovastatin. Archives of internal medicine, 1990, Volume: 150, Issue:6 Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Drug Therapy, Combi	1990
Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. The American journal of cardiology, 1989, May-02, Volume: 63, Issue:16 Topics: Adult; Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Coronary Disease; Double-Blind	1989
Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins. JAMA, 1985, Apr-26, Volume: 253, Issue:16 Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hyperlipide	1985

Article	Year
Expeditious and convenient synthesis of pregnanes and its glycosides as potential anti-dyslipidemic and anti-oxidant agents. Bioorganic & medicinal chemistry, 2007, Jul-01, Volume: 15, Issue:13 Topics: Animals; Antioxidants; Cholesterol; Glycosides; Hyperlipidemias; Hypolipidemic Agents; Indicators an	2007
Novel keto-enamine Schiffs bases from 7-hydroxy-4-methyl-2-oxo-2H-benzo[h] chromene-8,10-dicarbaldehyde as potential antidyslipidemic and antioxidant agents. European journal of medicinal chemistry, 2008, Volume: 43, Issue:11 Topics: Amines; Animals; Antioxidants; Coumarins; Female; Free Radicals; Hyperlipidemias; Hypolipidemic Agen	2008
Design, synthesis and hypolipidemic activity of novel 2-(naphthalen-2-yloxy)propionic acid derivatives as desmethyl fibrate analogs. European journal of medicinal chemistry, 2009, Volume: 44, Issue:10 Topics: Animals; Cholesterol, Dietary; Gemfibrozil; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL	2009
Synthesis of novel benzocoumarin derivatives as lipid lowering agents. Bioorganic & medicinal chemistry letters, 2010, May-15, Volume: 20, Issue:10 Topics: Animals; Coumarins; Hyperlipidemias; Hypolipidemic Agents; Rats; Structure-Activity Relationship	2010
Indole-based fibrates as potential hypolipidemic and antiobesity agents. Journal of medicinal chemistry, 2012, Mar-22, Volume: 55, Issue:6 Topics: Animals; Anti-Obesity Agents; Bile Acids and Salts; Butyrates; Dietary Fats; Fatty Liver; Feces; Fee	2012
Discovery of amide based fibrates as possible antidyslipidemic and antioxidant agents. European journal of medicinal chemistry, 2012, Volume: 57 Topics: Amides; Animals; Antioxidants; Enzyme Activation; Fibric Acids; Free Radicals; Hyperlipidemias; Hypo	2012
Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity. European journal of medicinal chemistry, 2013, Volume: 69 Topics: Animals; Antioxidants; Disease Models, Animal; Diterpenes; Humans; Hyperlipidemias; Hypolipidemic Ag	2013
Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:19 Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Female; Fenofibrate; Gemfibrozil; Glucose-6	2020
Design, synthesis, and antihyperlipidemic evaluation of novel 2-[1-(substitutedphenyl)-4-oxo-azetidin-2-yl]-5,6-disubstitutedthieno[2,3-d]pyrimidin-4(3H)-ones. Archiv der Pharmazie, 2013, Volume: 346, Issue:8 Topics: Animals; Azetidines; Biomarkers; Cholesterol; Disease Models, Animal; Drug Design; Gemfibrozil; Hype	2013
Drugs for lipids. Treatment guidelines from the Medical Letter, 2014, Volume: 12, Issue:137 Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils	2014
Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study. Current drug discovery technologies, 2015, Volume: 12, Issue:3 Topics: Amides; Animals; Cholesterol, HDL; Disease Models, Animal; Ethanolamine; Gemfibrozil; Humans; Hyperl	2015
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. Steroids, 2008, Volume: 73, Issue:11 Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxy	2008
Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2011, Jun-14, Volume: 43, Issue:3 Topics: Chromatography, High Pressure Liquid; Esters; Gemfibrozil; Half-Life; Humans; Hydrogen-Ion Concentra	2011
Eruptive xanthomas. Dermatology online journal, 2001, Volume: 7, Issue:2 Topics: Adult; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Xanthom	2001
Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis, 2002, Volume: 165, Issue:1 Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; H	2002
Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. WMJ : official publication of the State Medical Society of Wisconsin, 2002, Volume: 101, Issue:7 Topics: Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito	2002
Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy. The American journal of cardiology, 2002, Dec-15, Volume: 90, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Gem	2002
Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacotherapy, 2002, Volume: 22, Issue:12 Topics: Aged; Chi-Square Distribution; Coronary Disease; Cross-Over Studies; Female; Fenofibrate; Gemfibrozi	2002
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). The American journal of cardiology, 2003, Jan-15, Volume: 91, Issue:2 Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female	2003
Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk. Atherosclerosis, 2003, Volume: 169, Issue:2 Topics: Antibodies; Chaperonin 60; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypertension; Hyp	2003
Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. Journal of medicinal food, 2003,Summer, Volume: 6, Issue:2 Topics: Animals; Bass; Cholesterol, LDL; Cholesterol, VLDL; Disease Models, Animal; Feces; Fish Oils; Gemfib	2003
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). The American journal of cardiology, 2003, Oct-01, Volume: 92, Issue:7 Topics: Age Factors; Bezafibrate; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluv	2003
Possible differences between fibrates in pharmacokinetic interactions with statins. Archives of internal medicine, 2003, Oct-27, Volume: 163, Issue:19 Topics: Drug Interactions; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidem	2003
Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:2 Topics: Acute Kidney Injury; Adult; Creatinine; Diabetes Mellitus, Type 1; Gemfibrozil; Humans; Hyperlipidem	2004
Risk of adverse events with fibrates. The American journal of cardiology, 2004, Oct-01, Volume: 94, Issue:7 Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidem	2004
The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy. Thrombosis research, 2005, Volume: 115, Issue:4 Topics: Bezafibrate; Case-Control Studies; Female; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolip	2005
The role of fibrates in a statin world. Archives of internal medicine, 2006, Apr-10, Volume: 166, Issue:7 Topics: Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperl	2006
[Fibrate-induced changes in the serum lipid contents of individual C16 and C18 fatty acids in patients with hyperlipidemia]. Klinicheskaia laboratornaia diagnostika, 2006, Issue:4 Topics: Fatty Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Linoleic Acid; Lipids; Olei	2006
Reproducible tendinitis-like symptoms related to statin therapy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2006, Volume: 12, Issue:6 Topics: Adult; Aged; Gemfibrozil; Humans; Hyperlipidemias; Male; Simvastatin; Tendinopathy	2006
Synthesis and antihyperlipidemic activity of some novel condensed 2-chloroalkyl-4-chloro/hydroxy-5,6-disubstituted pyrimidines. Arzneimittel-Forschung, 2007, Volume: 57, Issue:9 Topics: Alkanes; Animals; Chemical Phenomena; Chemistry, Physical; Cholesterol; Gemfibrozil; Hyperlipidemias	2007
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3 Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil;	2008
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases. Postgraduate medicine, 1983, Volume: 73, Issue:4 Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil	1983
Consensus conference: Treatment of hypertriglyceridemia. JAMA, 1984, Mar-02, Volume: 251, Issue:9 Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro	1984
Hyperlipidemia: reducing the chances of cardiovascular disease. Geriatrics, 1984, Volume: 39, Issue:7 Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemia	1984
Gemfibrozil for hyperlipidemia. The Medical letter on drugs and therapeutics, 1982, Jun-25, Volume: 24, Issue:612 Topics: Cholesterol; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Pentanoic Acids; Triglyceri	1982
Studies on hypoxic dyslipidaemia. Effect of lipid modulating drugs. Acta medica Scandinavica. Supplementum, 1982, Volume: 668 Topics: Altitude; Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Decompression; Femal	1982
Repeated blood donation effective in treating hyperlipidemia. The Journal of the Association of Physicians of India, 1994, Volume: 42, Issue:6 Topics: Adult; Blood Donors; Bloodletting; Cholesterol; Combined Modality Therapy; Diet, Fat-Restricted; Gem	1994
Criteria for use of hypolipidemic agents in adults. American journal of hospital pharmacy, 1994, Nov-15, Volume: 51, Issue:22 Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Gemfibrozil; Humans; Hydr	1994
Safety of combined pravastatin-gemfibrozil therapy. The American journal of cardiology, 1994, Sep-01, Volume: 74, Issue:5 Topics: Cholesterol, LDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Pravastatin	1994
An interaction between Gemfibrozil and alpha 1-antitrypsin. Journal of internal medicine, 1994, Volume: 236, Issue:3 Topics: alpha 1-Antitrypsin; Drug Interactions; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged; Obe	1994
Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants. Nephron, 1994, Volume: 66, Issue:2 Topics: Acute Kidney Injury; Gemfibrozil; Heart Transplantation; Humans; Hyperlipidemias; Leprostatic Agents	1994
[Gemfibrozil in the treatment of lipid metabolism disorders]. Klinicheskaia meditsina, 1994, Volume: 72, Issue:1 Topics: Adult; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Exercise Test; Femal	1994
Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil. Connecticut medicine, 1993, Volume: 57, Issue:9 Topics: Acute Kidney Injury; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Ma	1993
[Gemfibrozil-induced myopathy]. Harefuah, 1993, Nov-01, Volume: 125, Issue:9 Topics: Diabetes Complications; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney Failure, Chronic; Middl	1993
Two follow-up studies of preventive lipid-lowering trials support the validity of the lipid hypothesis. Journal of internal medicine, 1994, Volume: 235, Issue:1 Topics: Clinical Trials as Topic; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias;	1994
Hyperlipidemia and hypertension: impact of steroid withdrawal. Transplantation proceedings, 1993, Volume: 25, Issue:4 Suppl 3 Topics: Adrenal Cortex Hormones; Cholestyramine Resin; Female; Gemfibrozil; Heart Transplantation; Humans; H	1993
Seasonal variation in high density lipoprotein cholesterol. Atherosclerosis, 1993, Volume: 100, Issue:2 Topics: Adult; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged;	1993
Dyslipidemia. The Journal of family practice, 1993, Volume: 37, Issue:2 Topics: Combined Modality Therapy; Exercise; Gemfibrozil; Humans; Hyperlipidemias	1993
Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. The Medical journal of Australia, 1993, Jan-04, Volume: 158, Issue:1 Topics: Acute Disease; Biopsy; Compartment Syndromes; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney F	1993
Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. Scandinavian journal of urology and nephrology, 1993, Volume: 27, Issue:1 Topics: Adult; Aged; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; H	1993
Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin. The American journal of cardiology, 1993, Jun-15, Volume: 71, Issue:16 Topics: Female; Gemfibrozil; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged;	1993
Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. Journal of clinical gastroenterology, 1995, Volume: 21, Issue:4 Topics: Acute Disease; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemi	1995
Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, 1995, Volume: 33, Issue:11 Topics: Adult; Aged; Alleles; Apolipoproteins; Apolipoproteins E; Cholesterol; Cholesterol, Dietary; Cholest	1995
Persistence of balloon-induced arterial injury with hyperlipidemia despite gemfibrozil. Japanese heart journal, 1996, Volume: 37, Issue:1 Topics: Analysis of Variance; Animals; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cholester	1996
Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. Clinical nephrology, 1996, Volume: 45, Issue:6 Topics: Adult; Aged; Cholesterol; Exercise; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agen	1996
Effect of a combination of gemfibrozil and niacin on lipid levels. Journal of clinical pharmacology, 1996, Volume: 36, Issue:8 Topics: Diet Therapy; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic	1996
Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron, 1996, Volume: 74, Issue:2 Topics: Acute Kidney Injury; Aged; Angiotensin-Converting Enzyme Inhibitors; Bicarbonates; Diabetes Mellitus	1996
Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism. Clinica chimica acta; international journal of clinical chemistry, 1996, Oct-15, Volume: 254, Issue:1 Topics: Aged; Anticholesteremic Agents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Huma	1996
The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1996, Volume: 11, Issue:11 Topics: Adult; Blood Coagulation; Cholesterol, HDL; Chronic Disease; Cytokines; Female; Gemfibrozil; Humans;	1996
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. Southern medical journal, 1997, Volume: 90, Issue:5 Topics: Anticholesteremic Agents; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; H	1997
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. Chest, 1997, Volume: 112, Issue:4 Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem	1997
Safe use of gemfibrozil in uremic patients on continuous ambulatory peritoneal dialysis. Nephron, 1998, Volume: 78, Issue:3 Topics: Aged; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Periton	1998
Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism: clinical and experimental, 1998, Volume: 47, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Data Interpretation, Statistical; Drug Int	1998
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 1998, Jun-25, Volume: 393, Issue:6687 Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cycloox	1998
Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. Chest, 1998, Volume: 114, Issue:2 Topics: Aged; Anticoagulants; Drug Interactions; Follow-Up Studies; Gemfibrozil; Hemorrhage; Humans; Hyperli	1998
Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes. Diabetes research and clinical practice, 1998, Volume: 42, Issue:3 Topics: 6-Ketoprostaglandin F1 alpha; 8,11,14-Eicosatrienoic Acid; Aged; Arachidonic Acid; Cholesterol; Diab	1998
Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol. Journal of the Formosan Medical Association = Taiwan yi zhi, 1999, Volume: 98, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Female; Gemfibr	1999
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. American heart journal, 1999, Volume: 138, Issue:1 Pt 1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturate	1999
Dual hepatic metabolism of cerivastatin--clarifications. The American journal of cardiology, 1999, Aug-15, Volume: 84, Issue:4 Topics: Aged; Drug Synergism; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-	1999
Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. Journal of chromatography. B, Biomedical sciences and applications, 2000, May-12, Volume: 741, Issue:2 Topics: Animals; Chromatography, High Pressure Liquid; Gemfibrozil; Glucuronides; Humans; Hyperlipidemias; H	2000
A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. Angiology, 2000, Volume: 51, Issue:8 Topics: Diabetes Mellitus; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Fatal Outcome;	2000
Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis. Southern medical journal, 2000, Volume: 93, Issue:8 Topics: Anti-Inflammatory Agents; Asthma; Biopsy; Causality; Drug Hypersensitivity; Endoscopy, Digestive Sys	2000
Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. The American journal of medicine, 2000, Aug-15, Volume: 109, Issue:3 Topics: Aged; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase In	2000
Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia. European journal of clinical investigation, 2000, Volume: 30, Issue:10 Topics: Animals; Antibodies; Aorta, Abdominal; Arteriosclerosis; Blood Platelets; Cholesterol; Disease Model	2000
A case for lipid-lowering? Diabetic medicine : a journal of the British Diabetic Association, 2000, Volume: 17 Suppl 2 Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Dise	2000
Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins. Current atherosclerosis reports, 2000, Volume: 2, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Evi	2000
Deterioration in renal function associated with fibrate therapy. Clinical nephrology, 2001, Volume: 55, Issue:1 Topics: Adult; Aged; Creatinine; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Ki	2001
Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS (London, England), 2001, Apr-13, Volume: 15, Issue:6 Topics: Acute Kidney Injury; Drug Therapy, Combination; Gemfibrozil; HIV Infections; HIV Protease Inhibitors	2001
Postprandial remnant-like lipoproteins in hypertriglyceridemia. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:7 Topics: Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins; Apolipoproteins B; Cholesterol; Fasting;	2001
Normocholesterolaemic dyslipidaemia: is there a role for fibrates? The Medical journal of Australia, 2001, Jun-04, Volume: 174, Issue:11 Topics: Algorithms; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Decision Trees; Gemfibrozil; Humans; Hy	2001
Normocholesterolaemic dysslipidaemia: is there a role for fibrates? The Medical journal of Australia, 2001, Jun-04, Volume: 174, Issue:11 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hyd	2001
Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect? Journal of clinical pharmacy and therapeutics, 2001, Volume: 26, Issue:6 Topics: Biological Availability; Cholinergic Agents; Cytochrome P-450 Enzyme System; Drug Interactions; Gemf	2001
Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet (London, England), 2001, Nov-24, Volume: 358, Issue:9295 Topics: Creatinine; Fenofibrate; Gemfibrozil; Glomerular Filtration Rate; Homocysteine; Humans; Hyperlipidem	2001
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore medical journal, 2001, Volume: 42, Issue:8 Topics: Acute Kidney Injury; Aged; Bezafibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypo	2001
Therapy and clinical trials. Current opinion in lipidology, 2002, Volume: 13, Issue:1 Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias;	2002
Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine. Clinical chemistry, 2002, Volume: 48, Issue:7 Topics: beta 2-Microglobulin; Biomarkers; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; K	2002
Sexual dysfunction after gemfibrozil. BMJ (Clinical research ed.), 1992, Sep-19, Volume: 305, Issue:6855 Topics: Erectile Dysfunction; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged	1992
Compliance with medication in the Helsinki Heart Study. European journal of clinical pharmacology, 1992, Volume: 42, Issue:1 Topics: Capsules; Creatinine; Digoxin; Female; Gemfibrozil; Humans; Hyperlipidemias; Male; Patient Complianc	1992
Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia. Annals of the Academy of Medicine, Singapore, 1992, Volume: 21, Issue:1 Topics: Cost-Benefit Analysis; Drug Evaluation; Female; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidem	1992
[The effect of gemfibrozil on serum apo C II and C III in diabetic hyperlipidemia]. Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 1991, Volume: 22, Issue:4 Topics: Aged; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; Diabetes Mellitus, Type 2; Femal	1991
[A long-term study on blood lipids after gemfibrozil]. Zhonghua xin xue guan bing za zhi, 1991, Volume: 19, Issue:6 Topics: Adult; Aged; Cholesterol; Female; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged; Triglycer	1991
Gemfibrozil-induced impotence. Lancet (London, England), 1990, Dec-01, Volume: 336, Issue:8727 Topics: Erectile Dysfunction; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged	1990
Gemfibrozil in familial and type V hyperlipidaemias. Report of 3 cases. The Journal of the Association of Physicians of India, 1990, Volume: 38, Issue:11 Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Com	1990
Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Annals of internal medicine, 1990, Feb-01, Volume: 112, Issue:3 Topics: Acute Kidney Injury; Biological Assay; Drug Interactions; Drug Therapy, Combination; Gemfibrozil; Hu	1990
Effect of gemfibrozil on erythrocyte membrane lipids in geriatric patients. Experimental gerontology, 1990, Volume: 25, Issue:1 Topics: Aged; Aged, 80 and over; Erythrocyte Membrane; Gemfibrozil; Humans; Hyperlipidemias; Lipid Metabolis	1990
Gemfibrozil in hyperlipidaemia: an open, single blind trial. The Journal of the Association of Physicians of India, 1990, Volume: 38, Issue:2 Topics: Adult; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug E	1990
Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions. Metabolism: clinical and experimental, 1989, Volume: 38, Issue:10 Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, HDL	1989
[Efficacy of blood lipid normalization and tolerance in dyslipidemic patients treated for 18 months with fibric acid derivatives]. La Clinica terapeutica, 1989, Dec-31, Volume: 131, Issue:6 Topics: Adult; Bezafibrate; Drug Evaluation; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Lipi	1989
Treatment of hyperlipidaemias. Current avenues and new horizons. Australian family physician, 1989, Volume: 18, Issue:9 Topics: Cholestyramine Resin; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; H	1989
[Gemfibrozil in the treatment of hyperlipidemia]. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1989, Volume: 43, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Cholesterol, HDL; Drug Evaluation; Female; Gemfibrozil;	1989
Treating hyperlipidemia, Part III: Drug therapy. Geriatrics, 1987, Volume: 42, Issue:8 Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias	1987
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening. Atherosclerosis, 1988, Volume: 70, Issue:1-2 Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofib	1988
[Effect of gemfibrozil on serum lipids, lipoproteins and apolipoproteins in diabetes mellitus with dyslipidemia]. Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 1988, Volume: 19, Issue:3 Topics: Aged; Apolipoproteins; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipi	1988
[Strains and species differences in experimental hyperlipidemia]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1986, Volume: 87, Issue:3 Topics: Animals; Clofibrate; Disease Models, Animal; Gemfibrozil; Glycerides; Hyperlipidemias; Hypolipidemic	1986
Medical management of hyperlipidemia and the role of probucol. The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16 Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem	1986
The hypolipidemic effect of gemfibrozil on hyperlipidemia in patients with non-insulin-dependent diabetes mellitus. Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association, 1986, Volume: 85, Issue:5 Topics: Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hyperlipidemias; Hyp	1986
Treatment of hyperlipidemia with gemfibrozil. The Journal of cardiovascular nursing, 1987, Volume: 1, Issue:4 Topics: Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Pentanoic Acids; Valerates	1987
Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. The Journal of laboratory and clinical medicine, 1987, Volume: 110, Issue:3 Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Female; Gemfibrozil;	1987
Current pharmacologic treatment of elevated serum cholesterol. Circulation, 1987, Volume: 76, Issue:3 Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co	1987
Gemfibrozil has antilipemic effects on diabetic patients with hyperlipidemia. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1987, Volume: 39, Issue:1 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Gemfibrozil; Humans; Hyperlipidemia	1987
Adverse effects of the treatment for hyperlipidemia. Cardiology clinics, 1986, Volume: 4, Issue:1 Topics: Anion Exchange Resins; Anticholesteremic Agents; Bibliographies as Topic; Clofibrate; Diet; Drug The	1986

gemfibrozil and Hyperlipemia